These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14996527)

  • 1. Accounting- versus economic-based rates of return: implications for profitability measures in the pharmaceutical industry.
    Skrepnek GH
    Clin Ther; 2004 Jan; 26(1):155-74. PubMed ID: 14996527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Financial risk of the biotech industry versus the pharmaceutical industry.
    Golec J; Vernon JA
    Appl Health Econ Health Policy; 2009; 7(3):155-65. PubMed ID: 19799470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profitability of Large Pharmaceutical Companies Compared With Other Large Public Companies.
    Ledley FD; McCoy SS; Vaughan G; Cleary EG
    JAMA; 2020 Mar; 323(9):834-843. PubMed ID: 32125401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Labor Costs Affect Innovation Output in Pharmaceutical Companies: Evidence from China.
    Chen Y; He Q; Wang T
    Inquiry; 2024; 61():469580241246965. PubMed ID: 38726640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microcap pharmaceutical firms: linking drug pipelines to market value.
    Beach R
    J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dividend policy issues in the European pharmaceutical industry: new empirical evidence.
    Basse T; Schwarzbach C; Graf von der Schulenburg JM
    Eur J Health Econ; 2023 Jul; 24(5):803-816. PubMed ID: 36018442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
    DiMasi JA
    Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intellectual Capital and Financial Performance: Comparison With Financial and Pharmaceutical Industries in Vietnam.
    Zhang XB; Duc TP; Burgos Mutuc E; Tsai FS
    Front Psychol; 2021; 12():595615. PubMed ID: 33841234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic and non-economic determinants of Iranian pharmaceutical companies' financial performance: an empirical study.
    Masoumi M; Ebadi Fard Azar F; RezaPour A; Mehrara M
    BMC Health Serv Res; 2019 Dec; 19(1):1011. PubMed ID: 31888627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic return of clinical trials performed under the pediatric exclusivity program.
    Li JS; Eisenstein EL; Grabowski HG; Reid ED; Mangum B; Schulman KA; Goldsmith JV; Murphy MD; Califf RM; Benjamin DK
    JAMA; 2007 Feb; 297(5):480-8. PubMed ID: 17284698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profitability and risk-return comparison across health care industries, evidence from publicly traded companies 2010-2019.
    Bai G; Rajgopal S; Srivastava A; Zhao R
    PLoS One; 2022; 17(11):e0275245. PubMed ID: 36383519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining the link between price regulation and pharmaceutical R&D investment.
    Vernon JA
    Health Econ; 2005 Jan; 14(1):1-16. PubMed ID: 15386673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wise Investment? Modeling Industry Profitability and Risk of Targeted Chemotherapy for Incurable Solid Cancers.
    Conter HJ; Chu QSC
    J Oncol Pract; 2012 Mar; 8(2):69. PubMed ID: 29447097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting principles, revenue recognition, and the profitability of pharmacy benefit managers.
    McLean RA; Garis RI
    Res Social Adm Pharm; 2005 Mar; 1(1):118-25. PubMed ID: 17138469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk-Return Analysis of the Biopharmaceutical Industry as Compared to Other Industries.
    Popa C; Holvoet K; Van Montfort T; Groeneveld F; Simoens S
    Front Pharmacol; 2018; 9():1108. PubMed ID: 30327601
    [No Abstract]   [Full Text] [Related]  

  • 19. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring the efficiency of large pharmaceutical companies: an industry analysis.
    Gascón F; Lozano J; Ponte B; de la Fuente D
    Eur J Health Econ; 2017 Jun; 18(5):587-608. PubMed ID: 27344446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.